Default company panoramic image

QuanDx Inc

QuanDx provides novel products to make molecular diagnosis easier, facilitate personalized medicine, and increase healthcare efficiency

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Menlo Park, CA, USA
  • Currency USD
  • Founded October 2010
  • Employees 3
  • Website

Company Summary

QuanDx’ vision is to develop and commercialize innovative research, particularly in vitro diagnostic assays based on proprietary molecular technology for use in clinical and research laboratories worldwide. Our patented technology is based on innovative Yin-Yang Probe, a double stranded probe offering multiple benefits in the design and function of molecular based assays with applications in cancer, cardiovascular and genetic disease etc.


  • Default avatar
    Matthew Lei
    CEO and President

    A seasoned executive with broad experience including his tenure He obtained his medical degree from Tongji Medical College, a PhD from Cornell University, and worked as a research associate at Memorial Sloan-Kettering Cancer Center.

  • Default avatar
    Graeme Duncan
    Vice President, Sales and Marketing

    30 years of sales and marketing management experience within the diagnostic market, the last fifteen years focused exclusively within early stage companies. Graeme was most recently employed as Director of Global Marketing for Invivoscribe and previously held senior positions with Ipsogen, Cytocell and Speywood Pharmaceuticals. Graeme began his commercial career at Ortho Diagnostic Systems, UK and was previously an MLSO with the UK’s NHS.

  • Default avatar
    Guo-liang Yu

    Prior to establish QuanDx Inc., Dr. Yu is the president, CEO and Chairman of the Board of Epitomics, acquired by Abcam in 2012. Dr.Yu has more than 12 years of experience in genomics and 24 years of experience in life sciences research.


  • Default avatar
    Seth Rubin from Ruskin Moscou Faltischek, P.C.
    Default avatar
    George Li

Previous Investors

  • Default avatar
    Private Investor